VISEN Pharmaceuticals Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Operating Revenue	0.17	-	-	-
Other Revenue	-0.03	2.78	-1.67	-2.3
Revenue	0.14	2.78	-1.67	-2.3
Revenue Growth (YoY)	-95.10%	-	-	-
Cost of Revenue	0.15	-	-	-
Gross Profit	-0.01	2.78	-1.67	-2.3
Selling, General & Admin	146.33	86.43	79.94	177.45
Research & Development	93.48	90.52	57.69	179.55
Operating Expenses	239.81	176.96	137.63	357
Operating Income	-239.82	-174.18	-139.3	-359.29
Interest Expense	-1.1	-0.16	-0.32	-0.62
Interest & Investment Income	11.78	6.77	11.15	5.57
Currency Exchange Gain (Loss)	-13.64	2.69	4.71	79.78
Other Non Operating Income (Expenses)	-10.64	-17.37	-16.28	-14.3
EBT Excluding Unusual Items	-253.42	-182.24	-140.05	-288.86
Gain (Loss) on Sale of Assets	-	-	-0.24	-0.1
Other Unusual Items	-	-	-109.28	-
Pretax Income	-253.42	-182.24	-249.57	-288.97
Net Income	-253.42	-182.24	-249.57	-288.97
Net Income to Common	-253.42	-182.24	-249.57	-288.97
Shares Outstanding (Basic)	104	94	94	-
Shares Outstanding (Diluted)	104	94	94	-
Shares Change (YoY)	10.71%	-	-	-
EPS (Basic)	-2.44	-1.95	-2.67	-
EPS (Diluted)	-2.44	-1.95	-2.67	-
Free Cash Flow	-	-140.98	-271.83	-248.03
Free Cash Flow Per Share	-	-1.51	-2.90	-
Gross Margin	-7.35%	100.00%	-	-
Operating Margin	-176338.97%	-6272.16%	-	-
Profit Margin	-186339.71%	-6562.55%	-	-
Free Cash Flow Margin	-	-5076.52%	-	-
EBITDA	-239.11	-173.46	-137.79	-357.55
D&A For EBITDA	0.72	0.72	1.51	1.74
EBIT	-239.82	-174.18	-139.3	-359.29

Source: S&P Global Market Intelligence. Standard template. Financial Sources.